Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07804966) titled 'Sac-TMT in Vaginal and Vulvar Cancers' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Latin American Cooperative Oncology Group
Condition:
Vaginal Squamous Cell Carcinoma
Vulvar Squamous Cell Carcinoma
Intervention:
Drug: Sacituzumab Tirumotecan (sac-TMT)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 2027
Target Sample Size: 48
Countries of Recruitment:
Brazil
To know more, visit https://clinicaltrials.gov/study/NCT07...